As of December 31, 2025, Dogwood (DWTX) Therapeutics’ cash and cash equivalents totaled $6.5 million. The Company believes that the cash and cash equivalents on hand at December 31, 2025 together with the net proceeds received in January 2026 of $11.4 million after deducting placement agent fees and offering expenses payable by the Company, is expected to fund operations through the Halneuron Phase 2b final data readout and into the fourth quarter of 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DWTX:
- Dogwood reports Q4 EPS (26c) vs. ($6.29) last year
- Dogwood Therapeutics Shareholders Approve Warrant Exercise Proposal
- Dogwood Therapeutics: Strengthened Capital Structure, Advancing Pain Pipeline, and Extended IP Support a Buy-Rated Risk-Reward Profile
- Dogwood announces 50% enrollment in ongoing Halneuron Phase 2b trial
- Dogwood Therapeutics outlines 2026 plans for pain pipeline